DLD Asset Management’s Lipocine LPCN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2018
Q1
Sell
-16,406
Closed -$959K 112
2017
Q4
$959K Sell
16,406
-7,712
-32% -$480K 0.07% 46
2017
Q3
$1.62M Buy
24,118
+13,365
+124% +$966K 0.16% 41
2017
Q2
$737K Buy
10,753
+6,341
+144% +$414K 0.1% 49
2017
Q1
$292K Buy
+4,412
New +$286K 0.05% 61

Other funds holding LPCN

DLD Asset Management's LPCN Position: Q1 2018 in Review

DLD Asset Management sold out of Lipocine (LPCN) in Q1 2018, closing a stake of 7,000 shares — an estimated $195K sold.

DLD Asset Management first reported a position in LPCN in Q2 2017 and held it in 3 quarters. The position peaked at $1.59M in Q3 2017. 27 funds tracked by Wall St. Rank hold LPCN as of Q1 2018.

  • DLD Asset Management reported no remaining Lipocine position as of Q1 2018 after selling out during the quarter.
  • DLD Asset Management sold 7,000 Lipocine shares in Q1 2018, an estimated $195K.
  • DLD Asset Management first reported a position in Lipocine in Q2 2017 and held it in 3 quarters.
  • DLD Asset Management's Lipocine position peaked at $1.59M in Q3 2017.
  • 27 funds tracked by Wall St. Rank held Lipocine as of Q1 2018.

Based on DLD Asset Management's 13F filing for Q1 2018, filed 14 May 2018.